{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:26:42Z","timestamp":1756463202340,"version":"3.33.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010438","name":"Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu","doi-asserted-by":"publisher","award":["502-14-12253630\u201345064"],"award-info":[{"award-number":["502-14-12253630\u201345064"]}],"id":[{"id":"10.13039\/501100010438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-85534-w","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T09:37:05Z","timestamp":1736761025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of the use of omeprazole versus famotidine on the kidney transplant function: a randomized controlled study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9773-1461","authenticated-orcid":false,"given":"Mi\u0142osz","family":"Miedziaszczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-0709","authenticated-orcid":false,"given":"Marek","family":"Karczewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2291-1484","authenticated-orcid":false,"given":"Ilona","family":"Idasiak-Piechocka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"85534_CR1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/FTD.0b013e318271b6e6","volume":"34","author":"W Zhao","year":"2012","unstructured":"Zhao, W. et al. Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole. Ther. Drug Monit. 34, 739\u2013741. https:\/\/doi.org\/10.1097\/FTD.0b013e318271b6e6 (2012).","journal-title":"Ther. Drug Monit."},{"key":"85534_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2133\/dmpk.22.441","volume":"22","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab. Pharmacokinet 22, 441\u2013444. https:\/\/doi.org\/10.2133\/dmpk.22.441 (2007).","journal-title":"Drug Metab. Pharmacokinet"},{"key":"85534_CR3","doi-asserted-by":"publisher","first-page":"1352323","DOI":"10.3389\/fphar.2024.1352323","volume":"15","author":"M Miedziaszczyk","year":"2024","unstructured":"Miedziaszczyk, M., Karczewski, M., Grabowski, T., Wolc, A. & Idasiak-Piechocka, I. Assessment of omeprazole and famotidine effects on the pharmacokinetics of tacrolimus in patients following kidney transplant-randomized controlled trial. Front. Pharmacol. 15, 1352323. https:\/\/doi.org\/10.3389\/fphar.2024.1352323 (2024).","journal-title":"Front. Pharmacol."},{"key":"85534_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0090-9556(24)15298-1","volume":"27","author":"A Moller","year":"1999","unstructured":"Moller, A. et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab. Dispos. 27, 633\u2013636 (1999).","journal-title":"Drug Metab. Dispos."},{"key":"85534_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115149","volume":"166","author":"M Miedziaszczyk","year":"2023","unstructured":"Miedziaszczyk, M. & Idasiak-Piechocka, I. Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients\u2014A review. Biomed. Pharmacother. 166, 115149. https:\/\/doi.org\/10.1016\/j.biopha.2023.115149 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"85534_CR6","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1016\/s0041-1345(02)03409-7","volume":"34","author":"F Itagaki","year":"2002","unstructured":"Itagaki, F., Homma, M., Yuzawa, K., Fukao, K. & Kohda, Y. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Transplant. Proc. 34, 2777\u20132778. https:\/\/doi.org\/10.1016\/s0041-1345(02)03409-7 (2002).","journal-title":"Transplant. Proc."},{"key":"85534_CR7","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s10620-017-4725-5","volume":"62","author":"K Wijarnpreecha","year":"2017","unstructured":"Wijarnpreecha, K. et al. Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: A meta-analysis. Dig. Dis. Sci. 62, 2821\u20132827. https:\/\/doi.org\/10.1007\/s10620-017-4725-5 (2017).","journal-title":"Dig. Dis. Sci."},{"key":"85534_CR8","doi-asserted-by":"publisher","first-page":"21169","DOI":"10.1038\/s41598-023-48430-9","volume":"13","author":"T Kweon","year":"2023","unstructured":"Kweon, T. et al. Proton pump inhibitors and chronic kidney disease risk: A comparative study with histamine-2 receptor antagonists. Sci. Rep. 13, 21169. https:\/\/doi.org\/10.1038\/s41598-023-48430-9 (2023).","journal-title":"Sci. Rep."},{"key":"85534_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.transproceed.2017.01.029","volume":"49","author":"HS Ciftci","year":"2017","unstructured":"Ciftci, H. S. et al. Influence of proton pump inhibitors on mycophenolic acid pharmacokinetics in patients with renal transplantation and the relationship with cytochrome 2C19 gene polymorphism. Transplant. Proc. 49, 490\u2013496. https:\/\/doi.org\/10.1016\/j.transproceed.2017.01.029 (2017).","journal-title":"Transplant. Proc."},{"key":"85534_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1526924816669725","volume":"27","author":"GE Rouse","year":"2017","unstructured":"Rouse, G. E., Hardinger, K., Tsapepas, D. & Tichy, E. M. A comparison of histamine receptor antagonists versus proton pump inhibitor gastrointestinal ulcer prophylaxis in kidney transplant recipients. Prog. Transplant. 27, 4\u20139. https:\/\/doi.org\/10.1177\/1526924816669725 (2017).","journal-title":"Prog. Transplant."},{"key":"85534_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s001470050073","volume":"10","author":"I Skala","year":"1997","unstructured":"Skala, I., Mareckova, O., Vitko, S., Matl, I. & Lacha, J. Prophylaxis of acute gastroduodenal bleeding after renal transplantation. Transpl. Int. 10, 375\u2013378. https:\/\/doi.org\/10.1007\/s001470050073 (1997).","journal-title":"Transpl. Int."},{"key":"85534_CR12","first-page":"86","volume":"72","author":"GA van Boekel","year":"2014","unstructured":"van Boekel, G. A., Kerkhofs, C. H., van de Logt, F. & Hilbrands, L. B. Proton pump inhibitors do not increase the risk of acute rejection. Neth. J. Med. 72, 86\u201390 (2014).","journal-title":"Neth. J. Med."},{"key":"85534_CR13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/phar.2037","volume":"37","author":"KS Patel","year":"2017","unstructured":"Patel, K. S., Stephany, B. R., Barnes, J. F., Bauer, S. R. & Spinner, M. L. Renal transplant acute rejection with lower mycophenolate mofetil dosing and proton pump inhibitors or histamine-2 receptor antagonists. Pharmacotherapy 37, 1507\u20131515. https:\/\/doi.org\/10.1002\/phar.2037 (2017).","journal-title":"Pharmacotherapy"},{"key":"85534_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0009-9236(99)70129-3","volume":"65","author":"C Martinez","year":"1999","unstructured":"Martinez, C. et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin. Pharmacol. Ther. 65, 369\u2013376. https:\/\/doi.org\/10.1016\/S0009-9236(99)70129-3 (1999).","journal-title":"Clin. Pharmacol. Ther."},{"key":"85534_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchromb.2018.04.028","volume":"1087\u20131088","author":"S Mei","year":"2018","unstructured":"Mei, S. et al. Simultaneous determination of cyclosporine and tacrolimus in human whole blood by ultra-high performance liquid chromatography tandem mass spectrometry and comparison with a chemiluminescence microparticle immunoassay. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1087\u20131088, 36\u201342. https:\/\/doi.org\/10.1016\/j.jchromb.2018.04.028 (2018).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"85534_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111128","volume":"9","author":"G Tholking","year":"2014","unstructured":"Tholking, G. et al. The tacrolimus metabolism rate influences renal function after kidney transplantation. PLoS ONE 9, e111128. https:\/\/doi.org\/10.1371\/journal.pone.0111128 (2014).","journal-title":"PLoS ONE"},{"key":"85534_CR17","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1111\/ajt.15346","volume":"19","author":"C Susal","year":"2019","unstructured":"Susal, C. & Dohler, B. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report. Am. J. Transplant. 19, 2805\u20132813. https:\/\/doi.org\/10.1111\/ajt.15346 (2019).","journal-title":"Am. J. Transplant."},{"key":"85534_CR18","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1016\/j.transproceed.2005.09.126","volume":"37","author":"J Pascual","year":"2005","unstructured":"Pascual, J. et al. Interaction between omeprazole and tacrolimus in renal allograft recipients: A clinical-analytical study. Transplant. Proc. 37, 3752\u20133753. https:\/\/doi.org\/10.1016\/j.transproceed.2005.09.126 (2005).","journal-title":"Transplant. Proc."},{"key":"85534_CR19","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","volume":"357","author":"H Ekberg","year":"2007","unstructured":"Ekberg, H. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562\u20132575. https:\/\/doi.org\/10.1056\/NEJMoa067411 (2007).","journal-title":"N. Engl. J. Med."},{"key":"85534_CR20","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","volume":"9 Suppl 3","author":"KU Eckardt","year":"2009","unstructured":"Eckardt, K. U., Kasiske, B. L. & Zeier, M. G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9 Suppl 3, S1\u2013S155. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02834.x (2009).","journal-title":"Am. J. Transplant."},{"key":"85534_CR21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/phar.2470","volume":"40","author":"SE January","year":"2020","unstructured":"January, S. E., Progar, K., Nesselhauf, N. M., Hagopian, J. C. & Malone, A. F. Choice of acid suppressant therapy and long-term graft outcomes after kidney transplantation. Pharmacotherapy 40, 1082\u20131088. https:\/\/doi.org\/10.1002\/phar.2470 (2020).","journal-title":"Pharmacotherapy"},{"key":"85534_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/01.tp.0000436100.65983.10","volume":"97","author":"JP Knorr","year":"2014","unstructured":"Knorr, J. P. et al. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation 97, 518\u2013524. https:\/\/doi.org\/10.1097\/01.tp.0000436100.65983.10 (2014).","journal-title":"Transplantation"},{"key":"85534_CR23","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","volume":"91","author":"Y Xie","year":"2017","unstructured":"Xie, Y. et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 91, 1482\u20131494. https:\/\/doi.org\/10.1016\/j.kint.2016.12.021 (2017).","journal-title":"Kidney Int."},{"key":"85534_CR24","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s10157-021-02066-z","volume":"25","author":"Y Hatakeyama","year":"2021","unstructured":"Hatakeyama, Y., Horino, T., Matsumoto, T., Terada, Y. & Okuhara, Y. Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury. Clin. Exp. Nephrol. 25, 1087\u20131092. https:\/\/doi.org\/10.1007\/s10157-021-02066-z (2021).","journal-title":"Clin. Exp. Nephrol."},{"key":"85534_CR25","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.clinthera.2018.04.013","volume":"40","author":"FR Varallo","year":"2018","unstructured":"Varallo, F. R., de Nadai, T. R., de Oliveira, A. R. A. & Mastroianni, P. C. Potential adverse drug events and nephrotoxicity related to prophylaxis with omeprazole for digestive disorders: A prospective cohort study. Clin. Ther. 40, 973\u2013982. https:\/\/doi.org\/10.1016\/j.clinthera.2018.04.013 (2018).","journal-title":"Clin. Ther."},{"key":"85534_CR26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49883","volume":"15","author":"MP Parmar","year":"2023","unstructured":"Parmar, M. P. et al. Impact of proton pump inhibitors on kidney function and chronic kidney disease progression: A systematic review. Cureus 15, e49883. https:\/\/doi.org\/10.7759\/cureus.49883 (2023).","journal-title":"Cureus"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85534-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T21:41:46Z","timestamp":1736804506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85534-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85534"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85534-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving humans were approved by The Bioethical Commission at the Poznan University of Medical Sciences (No. 687\/20). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1805"}}